Table 1.
Patient characteristics
| All patients (%) | First-line gefitinib (%) | |
|---|---|---|
| Total number of patients | 1657 (100.0) | 929 (100) |
| Number of treatment regimens, median (range) | 2.0 (1–16) | 2.0 (1–16) |
| Year treatment commenced | ||
| 2008 | 194 (11.7) | 81 (8.7) |
| 2009 | 298 (18.0) | 170 (18.3) |
| 2010 | 361 (21.8) | 184 (19.8) |
| 2011 | 413 (24.9) | 234 (25.2) |
| 2012 | 391 (23.6) | 260 (28.0) |
| Sex | ||
| Male | 584 (35.2) | 270 (29.1) |
| Female | 1073 (64.8) | 659 (70.9) |
| Age, years median (range) | 67.0 (27–97) | 69.0 (27–97) |
| Histology | ||
| Ad | 1577 (95.2) | 898 (96.7) |
| Sq | 48 (2.9) | 19 (2.0) |
| Large | 5 (0.3) | 2 (0.2) |
| AdSq | 9 (0.5) | 5 (0.5) |
| Other | 18 (1.1) | 5 (0.5) |
| EGFR mutation type | ||
| Del 19 | 814 (49.1) | 467 (50.3) |
| L858R | 667 (40.3) | 383 (41.2) |
| Other | 146 (8.8) | 60 (6.5) |
| Del19 + L858R | 7 (0.4) | 5 (0.5) |
| Del19 + T790M | 4 (0.2) | 2 (0.2) |
| Del19 + other | 5 (0.3) | 3 (0.3) |
| L858R + T790M | 5 (0.3) | 3 (0.3) |
| L858R + other | 9 (0.5) | 6 (0.6) |
| Clinical stage | ||
| IIIB | 125 (7.5) | 44 (4.7) |
| IV | 1105 (66.7) | 600 (64.6) |
| Recurrence | 427 (25.8) | 285 (30.7) |
| Number of metastatic organs | ||
| 0 | 289 (17.4) | 154 (16.6) |
| 1 | 725 (43.8) | 394 (42.4) |
| 2 | 354 (21.4) | 214 (23.0) |
| ≥3 | 289 (17.4) | 167 (18.0) |
| Performance status | ||
| 0 | 654 (39.5) | 334 (36.0) |
| 1 | 681 (41.1) | 369 (39.7) |
| 2 | 117 (7.1) | 85 (9.1) |
| 3 | 81 (4.9) | 70 (7.5) |
| 4 | 12 (0.7) | 11 (1.2) |
| Unknown | 112 (6.8) | 60 (6.5) |
| Smokings | ||
| Smoker | 646 (39.0) | 306 (32.9) |
| Non-smoker | 981 (59.2) | 604 (65.0) |
| Unknown | 30 (1.8) | 19 (2.0) |
Ad, adenocarcinoma; Sq, squamous cell carcinoma; large, large cell carcinoma; AdSq, adenosquamous cell carcinoma.